Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine
20 déc. 2024 09h00 HE
|
Channel Therapeutics Corporation
FREEHOLD, N.J., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment...
Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model
18 déc. 2024 08h30 HE
|
Channel Therapeutics Corporation
FREEHOLD, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment...
Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates
21 nov. 2024 09h49 HE
|
Channel Therapeutics Corporation
“Channel Therapeutics” reflects the Company’s focus on developing therapeutics to treat pain utilizing sodium channel blockade and modulationNew name is in advance of multiple near-term data readouts ...
Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain
29 oct. 2024 08h30 HE
|
Chromocell Therapeutics Corporation
FREEHOLD, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
Chromocell to Present at Upcoming Fall Investor Conferences
28 oct. 2024 08h00 HE
|
Chromocell Therapeutics Corporation
FREEHOLD, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
Chromocell Announces Amendment to Stock Repurchase Plan
24 oct. 2024 08h45 HE
|
Chromocell Therapeutics Corporation
FREEHOLD, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
Chromocell to Present at the H.C. Wainwright 26th Annual Global Investment Conference
03 sept. 2024 09h00 HE
|
Chromocell Therapeutics Corporation
FREEHOLD, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
Chromocell Announces Stock Repurchase Plan
07 août 2024 08h45 HE
|
Chromocell Therapeutics Corporation
FREEHOLD, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...